IO Biotech secures €57.5 million loan facility from EIB to support cancer vaccine development, extending cash runway to 2026. IO Biotech has secured a loan facility of up to €57.5 million from the ...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio ® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment ...

Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1697959&tp_key=934ba9e309 A webcast replay of the Piper Sandler fireside chat will be available on IO ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win ® vaccine platform, ...

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

IO Biotech (Nasdaq: IOBT) is a biopharmaceutical company dedicated to transforming the treatment of cancer patients through the discovery and development of novel immune-modulating therapeutic ...

Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the ...

A webcast replay of the Piper Sandler fireside chat will be available on IO Biotech’s website at www.iobiotech.com for 90 days following the presentation. About IO102-IO103 IO102-IO103 is an ...